Pharmaxis (ASX: PXS, Nasdaq: PXSL) today announced that it had raised A$47 million
through a placement of 20 million shares at A$2.35 to Australian and international institutions and professional investors.
The placement strengthens the company's balance sheet as Pharmaxis moves toward the
European and U.S. commercial launch of its product Bronchitol for cystic fibrosis.

Full release - Pharmaxis Announces Placement of $47 Million and Share Purchase Plan (24KB)